Publication: Durability of bioprosthetic aortic valve replacement in patients under the age of 60 years — 1-year follow-up from the prospective INDURE registry
Authors
Meuris, Bart ; Roussel, Jean-Christian ; Borger, Michael A. ; Siepe, Matthias ; Stefano, Pierluigi ; Laufer, Günther ; Langanay, Thierry ; Theron, Alexis ; Grabenwöger, Martin ; Binder, Konrad ; Demers, Philippe ; Pesotto, Renzo ; Leeuwen, Wouter van ; Bourguignon, Thierry ; Cánovas López, Sergio ; Mariscalco, Giovanni ; Coscioni, Enrico ; Dagenais, Francois ; Wendler, Olaf ; Polvani, Gianluca ; Eden, Matthias ; Botta, Beate ; Bramlage, Peter ; De Paulis, Ruggero
item.page.secondaryauthor
item.page.director
Publisher
Oxford University Press
publication.page.editor
publication.page.department
DOI
https://doi.org/10.1093/icvts/ivad115
item.page.type
info:eu-repo/semantics/article
Description
© The Author(s) 2023. This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by/4.0/. This document is the Published version of a Published Work that appeared in final form in Interdisciplinary CardioVascular and Thoracic Surgery. To access the final edited and published work see https://doi.org/10.1093/icvts/ivad115
Abstract
OBJECTIVES: We report 1-year safety and clinical outcomes in patients <60 years undergoing bioprosthetic surgical aortic valve intervention. METHODS: The INSPIRIS RESILIA Durability Registry is a prospective, multicentre registry to assess clinical outcomes of patients <60 years. Patients with planned SAVR with or without concomitant replacement of the ascending aorta and/or coronary bypass surgery were included. Time-related valve safety, haemodynamic performance and quality of life (QoL) at 1 year were assessed. RESULTS: A total of 421 patients were documented with a mean age of 53.5 years, 76.5% being male and 27.2% in NYHA class III/IV. Outcomes within 30 days included cardiovascular-related mortality (0.7%), time-related valve safety (VARC-2; 5.8%), thromboembolic events (1.7%), valve-related life-threatening bleeding (VARC-2; 4.3%) and permanent pacemaker implantation (3.8%). QoL was significantly increased at 6 months and sustained at 1 year. Freedom from all-cause mortality at 1 year was 98.3% (95% confidence interval 97.1; 99.6) and 81.8% were NYHA I versus 21.9% at baseline. No patient developed structural valve deterioration stage 3 (VARC-3). The mean aortic pressure gradient was 12.6 mmHg at 1 year and the effective orifice area was 1.9 cm2. CONCLUSIONS: The 1-year data from the INSPIRIS RESILIA valve demonstrate good safety and excellent haemodynamic performance as well as an early QoL improvement.
publication.page.subject
Citation
Interdisciplinary CardioVascular and Thoracic Surgery 2023, 37(4), ivad115
item.page.embargo
Collections
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by/4.0/